OMCL

AI Memo

Omnicell

As of 2026-09-11/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-11 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

Titan XT shipment and conversion execution • 2026-12-31

Base target: $36 / p=50% prob

Biggest risk

The lowered bookings floor indicates weak timing visibility for large enterprise deployments. Some second-quarter profitability benefited from a $15 million tariff refund, while delayed approvals, contracting complexity and unproven OmniSphere monetization could defer growth. Recent executive open-market sales are a monitoring consideration, not evidence of deteriorating operations [#SEC-FORM4-2026-08-18].

Invalidation

Break below $24 or thesis failure.

What would change my mind?

Revenue growth, connected-device demand, services expansion and cost discipline support operating leverage. Titan XT conversions and eventual OmniSphere availability could strengthen refresh-cycle demand and recurring revenue if customer decisions convert on schedule.

Research note

Recommendation

—

Confidence

medium

As of

2026-09-11

Base target

$36

p=50%

Bull target

$45

p=25%

Bear target

$24

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Improved profitability versus bookings uncertainty
OmniSphere commercialization milestone
Revenue growth, connected-device demand, services expansion and cost discipline support operating leverage.

BearKey bullets

Analyst revision, options, short-interest and attributed post-release price-reaction evidence is unavailable.
Large customer approvals and contracting cycles may push product bookings and revenue into later periods.
OmniSphere ADS commercialization and monetization remain early, with general availability targeted for the first half of 2027.

WatchKey bullets

Titan XT shipment and conversion execution

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $36 (p=50%)

Target spread vs base: +25% / -33%

Scenario probabilities

Bull Target: $45 (p=25%)Base Target: $36 (p=50%)Bear Target: $24 (p=25%)

Commentary

Primary-source earnings evidence is modestly positive on revenue growth and raised profitability guidance, but the reduced bookings floor and decision-cycle uncertainty temper the signal. The stock's $32.25 anchor is below the prices associated with the cited July and August insider transactions, although that comparison does not establish causation. Social coverage is unavailable, and the zero-valued social, options, short-interest and employee fields indicate missing evidence rather than neutral readings. Post-print analyst revisions and trusted attribution for the market reaction are also unavailable, keeping the view monitoring-oriented.

As of 2026-09-11 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Improved profitability versus bookings uncertainty
OmniSphere commercialization milestone

Scenarios

Bull Target (Scenario probability)

$45 / p=25% prob

Base Target (Scenario probability)

$36 / p=50% prob

Bear Target (Scenario probability)

$24 / p=25% prob

Analysis 2026-09-11 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Titan XT shipment and conversion execution
Management indicated Titan XT shipments remain on track for the second half of 2026 and highlighted its first competitive conversion win of the year. Converting the broader pipeline into recognized revenue could improve confidence, while further customer-decision delays would weaken the signal [#PR-EARNINGS-2026-07-31].
Prob 55.00% • Move 12.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

Improved profitability versus bookings uncertainty
2026-10-31
Second-quarter revenue increased 7% to $312 million, while non-GAAP EPS rose to $0.94 and non-GAAP EBITDA reached $67 million. Omnicell raised full-year profitability guidance, but the lower product-bookings bound was reduced because customer approvals and contracting are taking longer. The $15 million tariff refund also makes the quarter's profitability less fully repeatable [#SEC-8K-2026-07-30].
Prob 65% • Move 8% • Priced-in 70%

Long-term Catalysts

Months to a year

OmniSphere commercialization milestone
2027-06-30
OmniSphere ADS general availability remains targeted for the first half of 2027. Successful commercialization could expand Omnicell's cloud-connected platform and recurring-revenue opportunity, but monetization is early and management has not yet provided enough evidence to underwrite rapid adoption [#PR-EARNINGS-2026-07-31].
Prob 50% • Move 18% • Priced-in 25%

Risks

Analyst revision, options, short-interest and attributed post-release price-reaction evidence is unavailable.
Large customer approvals and contracting cycles may push product bookings and revenue into later periods.
OmniSphere ADS commercialization and monetization remain early, with general availability targeted for the first half of 2027.
Second-quarter profitability included a $15 million tariff refund, limiting the quarter's usefulness as a clean run-rate benchmark.
The supplied peer set is loose and does not provide a strong direct valuation benchmark.
Titan XT pipeline interest may not translate into timely competitive conversions or shipments.

Peers

Symbol	Summary
INSP	Similar market-cap medtech reference, but its implantable-device model differs materially from Omnicell's medication-management automation and software exposure; useful mainly for small-cap medtech sentiment.
ABT	Diversified healthcare-equipment benchmark with far greater scale and business breadth. It offers broad sector context but is not a direct operating or valuation comparable.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-11

Loading AI feed…

Symbol

Summary

INSP

Similar market-cap medtech reference, but its implantable-device model differs materially from Omnicell's medication-management automation and software exposure; useful mainly for small-cap medtech sentiment.

ABT

Diversified healthcare-equipment benchmark with far greater scale and business breadth. It offers broad sector context but is not a direct operating or valuation comparable.